Drug Allergy Clinical Trial
Official title:
Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
This research study is evaluating a drug called omalizumab (brand name 'Xolair') as a potential treatment to be used in conjunction with drug desensitization to prevent reactions from recurring and allowing the participant to be treated with the chemotherapy the participant's oncologist prefers to give.
After the screening procedures confirm that eligibility:
- The participant will receive a dose of 300mg of omalizumab under the skin every four
weeks at three separate visits representing a treatment period of 12 weeks.
- During the entire course of the study, the participant will continue receiving their
chemotherapy per their oncologist's prescribed schedule via desensitization supervised
by an Allergy specialist from the BWH/DFCI Desensitization Team. The participant cannot
receive omalizumab on the same day as their desensitization however.
- A careful review of the participant's symptoms will be done with each desensitization
while on the study by filling out a questionnaire detailing what reactions, if any, the
participant experienced with each desensitization during the study period. Additionally,
the Allergy specialist will be documenting what complications, if any, were experienced
in the participant's medical record, and this note will also be collected as part of
their monitoring during the study period.
- The participant may have had skin testing to the agent they are being desensitized to in
the course of the study. This would have been part of the initial allergy consultation
prior to the participant's enrollment in the Desensitization Program. If the skin
testing was positive, the participant will have to undergo repeat skin testing to that
agent at the conclusion of the treatment period (week 12) to see if omalizumab is
effective in changing skin test outcomes in participant's chemotherapy allergy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06414694 -
Inpatient Penicillin Delabeling for Low-Risk Patients
|
Phase 4 | |
Completed |
NCT05706246 -
Perioperative Hypersensitivity in Children
|
N/A | |
Recruiting |
NCT04920721 -
Retrospective Study of Immediate Hypersensitivity (IHS) Reactions to Platinum Salts in the University Hospital of Nancy
|
||
Enrolling by invitation |
NCT03164044 -
Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy
|
||
Completed |
NCT02094638 -
Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study
|
N/A | |
Not yet recruiting |
NCT06399601 -
A Training Program of Drug Allergy for Healthcare Professionals
|
N/A | |
Completed |
NCT03784482 -
Multiple Drug Hypersensitivity Syndrome
|
||
Not yet recruiting |
NCT06406114 -
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
|
Phase 2 | |
Recruiting |
NCT05820802 -
High Dimensional Analysis of Immune Cells in Pediatric Patients
|